Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525GlobeNewsWire • 03/18/22
Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast CancerGlobeNewsWire • 03/10/22
Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO's European Lung Cancer Congress 2022GlobeNewsWire • 02/18/22
Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway InhibitorGlobeNewsWire • 02/11/22
Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003GlobeNewsWire • 12/02/21
Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod AlphaGlobeNewsWire • 11/19/21
Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod AlphaGlobeNewsWire • 11/15/21
Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway InhibitorGlobeNewsWire • 11/15/21
Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast DetailsGlobeNewsWire • 11/09/21
Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a Chemotherapy AgentGlobeNewsWire • 11/02/21
Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase IIIGlobeNewsWire • 10/29/21
Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021GlobeNewsWire • 09/21/21
Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002GlobeNewsWire • 09/01/21
Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003GlobeNewsWire • 08/05/21
Immutep Shares Are Trading Higher On Green Signal To Start Efti Combo Trial In First-Line Head & Neck CancerBenzinga • 07/06/21
Immutep To Initiate Efti Triple Combination Therapy Trial In Solid Tumors, Launches $60M PlacementBenzinga • 06/21/21